Increased C‐reactive protein levels in overweight and obese women taking exogenous hormones: the United Kingdom Women’s Heart Study (UKWHS)

Objective  Women’s cardiovascular risk factors, including inflammatory markers such as C‐reactive protein (CRP) which is emerging as a major association with cardiovascular disease (CVD) risk, can be influenced by the oral contraceptive (OC) pill in premenopausal and hormone replacement (HR) in postmenopausal women and by central adiposity which is associated with a heightened inflammatory state. The interaction between central obesity and different hormone use in both pre and postmenopausal women has not previously been reported in a study spanning the whole age range associated with hormone use.

[1]  N. Rifai,et al.  A comparison of the short-term effects of oral conjugated equine estrogens versus transdermal estradiol on C-reactive protein, other serum markers of inflammation, and other hepatic proteins in naturally menopausal women. , 2008, The Journal of clinical endocrinology and metabolism.

[2]  P. Libby,et al.  Baseline characteristics of participants in the JUPITER trial, a randomized placebo-controlled primary prevention trial of statin therapy among individuals with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein. , 2007, The American journal of cardiology.

[3]  J. Danesh,et al.  Associations of plasma fibrinogen levels with established cardiovascular disease risk factors, inflammatory markers, and other characteristics: individual participant meta-analysis of 154,211 adults in 31 prospective studies: the fibrinogen studies collaboration. , 2007, American journal of epidemiology.

[4]  J. Danesh,et al.  Triglycerides and the Risk of Coronary Heart Disease: 10 158 Incident Cases Among 262 525 Participants in 29 Western Prospective Studies , 2007, Circulation.

[5]  N. Paynter,et al.  The effect of weight loss on C-reactive protein: a systematic review. , 2007, Archives of internal medicine.

[6]  G. Lowe.  Update on the Cardiovascular Risks of Hormone Replacement Therapy , 2007, Women's health.

[7]  S. Shapiro,et al.  Recent epidemiological evidence relevant to the clinical management of the menopause , 2007, Climacteric : the journal of the International Menopause Society.

[8]  G. Lowe,et al.  C-reactive protein and cardiovascular disease: Weighing the evidence , 2006, Current atherosclerosis reports.

[9]  E. Salpeter,et al.  Meta‐analysis: effect of hormone‐replacement therapy on components of the metabolic syndrome in postmenopausal women , 2006, Diabetes, obesity & metabolism.

[10]  N. Bersinger,et al.  Serum leptin and C-reactive protein levels in the physiological spontaneous menstrual cycle in reproductive age women. , 2006, European journal of endocrinology.

[11]  P. Crosignani.  Hormones and cardiovascular health in women. , 2006, Human reproduction update.

[12]  C. Schalkwijk,et al.  No increase in C-reactive protein levels during intranasal compared to oral hormone therapy in healthy post-menopausal women. , 2006, Human reproduction.

[13]  Steven V. Ley,et al.  Targeting C-reactive protein for the treatment of cardiovascular disease , 2006, Nature.

[14]  Garnet L Anderson,et al.  Combined analysis of Women's Health Initiative observational and clinical trial data on postmenopausal hormone treatment and cardiovascular disease. , 2006, American journal of epidemiology.

[15]  A. Tonkin,et al.  Hormone therapy and cardiovascular disease: a systematic review and meta-analysis , 2006, Journal of Family Planning and Reproductive Health Care.

[16]  S. Grundy,et al.  Metabolic syndrome: connecting and reconciling cardiovascular and diabetes worlds. , 2006, Journal of the American College of Cardiology.

[17]  A. Tonkin,et al.  Systematic review: Hormone therapy and cardiovascular disease: a systematic review and meta‐analysis , 2005 .

[18]  D. Herrington,et al.  Effects of hormone therapyon C-reactive protein and IL-6 in postmenopausal women: a review article , 2005, Climacteric : the journal of the International Menopause Society.

[19]  Jing Ma,et al.  Inflammatory markers and the risk of coronary heart disease in men and women. , 2004, The New England journal of medicine.

[20]  G. Lowe,et al.  Hormone replacement therapy and cardiovascular disease: increased risks of venous thromboembolism and stroke, and no protection from coronary heart disease , 2004, Journal of internal medicine.

[21]  G A Colditz,et al.  Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. , 2004, Preventive medicine.

[22]  J. Schlesselman,et al.  Safety concerns and health benefits associated with oral contraception. , 2004, American journal of obstetrics and gynecology.

[23]  Vilmundur Gudnason,et al.  C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. , 2004, The New England journal of medicine.

[24]  S. Phinney,et al.  Oral contraceptive use and increased plasma concentration of C-reactive protein. , 2003, Life sciences.

[25]  C. Kluft,et al.  Pro-inflammatory effects of oestrogens during use of oral contraceptives and hormone replacement treatment. , 2002, Vascular pharmacology.

[26]  Charles Kooperberg,et al.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. , 2002, JAMA.

[27]  Deborah Grady,et al.  Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). , 2002, JAMA.

[28]  G. Watt,et al.  Different Effects of Oral and Transdermal Hormone Replacement Therapies on Factor IX, APC Resistance, t-PA, PAI and C-reactive Protein , 2001, Thrombosis and Haemostasis.

[29]  F. Grodstein,et al.  Postmenopausal Hormone Use and Secondary Prevention of Coronary Events in the Nurses' Health Study: A Prospective, Observational Study , 2001, Annals of Internal Medicine.

[30]  S. Johnston,et al.  Ischemic stroke risk with oral contraceptives: A meta-analysis. , 2000, JAMA.

[31]  P. Ridker,et al.  C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. , 2000, The New England journal of medicine.

[32]  M. Visser,et al.  Elevated C-reactive protein levels in overweight and obese adults. , 1999, JAMA.

[33]  J. Urquhart,et al.  Venous thromboembolism amng new users of different oral contraceptives. , 1999, The Lancet.

[34]  M. Lansink,et al.  Effect of Oral Contraceptives on Haemostasis Variables , 1997, Thrombosis and Haemostasis.

[35]  I. Godsland,et al.  Sex, plasma lipoproteins, and atherosclerosis: prevailing assumptions and outstanding questions. , 1987, American heart journal.

[36]  B. Rifkind,et al.  Lipid Research Clinics Program reference values for hyperlipidemia and hypolipidemia. , 1983, JAMA.

[37]  M. Deurenberg-Yap,et al.  on Epidemic of Obesity , 2009 .

[38]  G. Colditz,et al.  Estrogen replacement therapy and coronary heart disease: A quantitative assessment of the epidemiologic evidence☆☆☆ , 1991 .